Which of the following statements about the adverse effects of cobimetinib is true?

Which of the following statements about the adverse effects of cobimetinib is true?

• A. It causes severe electrolyte imbalances.
• B. It commonly leads to retinopathy.
• C. It is associated with liver toxicity.
• D. It often causes skin rash.

Answer: (B)

The statement that cobimetinib commonly leads to retinopathy is indeed accurate. Cobimetinib is a MEK inhibitor used in the treatment of certain types of melanoma, and one of the known adverse effects associated with this medication is the development of retinopathy. This can manifest as changes in vision or other retinal issues, which is an important consideration for patients undergoing treatment with this drug. Furthermore, it is essential to note that while cobimetinib can cause various side effects, not every adverse effect is prominent or commonly associated with the drug. For example, severe electrolyte imbalances, liver toxicity, and skin rashes can occur, but they might not be as prevalent or significant as retinopathy in the context of this treatment. Thus, understanding the specific toxicities associated with cobimetinib is vital for patient management and monitoring during therapy.

The statement that cobimetinib commonly leads to retinopathy is indeed accurate. Cobimetinib is a MEK inhibitor used in the treatment of certain types of melanoma, and one of the known adverse effects associated with this medication is the development of retinopathy. This can manifest as changes in vision or other retinal issues, which is an important consideration for patients undergoing treatment with this drug.

Furthermore, it is essential to note that while cobimetinib can cause various side effects, not every adverse effect is prominent or commonly associated with the drug. For example, severe electrolyte imbalances, liver toxicity, and skin rashes can occur, but they might not be as prevalent or significant as retinopathy in the context of this treatment. Thus, understanding the specific toxicities associated with cobimetinib is vital for patient management and monitoring during therapy.